Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.

J Immunother Cancer · 2022 · PMC9577940 · PMID 36252998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, gene expression analysis showed a trend towards higher TILs, CD8 T cells, and PD-L1 at on-treatment as opposed to baseline trial biopsy time points ( figure 4A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.